Literature DB >> 28087401

How the EUCERD Joint Action supported initiatives on Rare Diseases.

Stephen Lynn1, Victoria Hedley2, Antonio Atalaia2, Teresinha Evangelista2, Kate Bushby2.   

Abstract

Joint Actions are successful initiatives from the European Commission (EC) that have helped to raise awareness and to bring significant benefit to those suffering from a rare disease (RD). In this paper, we will focus on the activities developed by the EUCERD Joint Action (EJA) and by the Orphanet Joint Action ("Orphanet Europe"). EUCERD Joint Action was co-funded by the EC and the Member States between 2012 and 2015 to help to define the activities and policies in the field of RD and foster exchange of experiences amongst Member States. This project is the continuation of previous efforts to turn RD a priority in the EC Health Programmes. "Orphanet Europe" was a Joint Action co-funded by INSERM, the French Directorate General for Health and the EC to address the need for a common portal that would gather the most update information regarding RD. This need was identified in the European Commission report "Rare Diseases: Europe's challenge" and in the Recommendation of the Council for a European RD portal. These joint actions have supported the policy development work of the European Commission, through the support of their committees for rare diseases. In this paper, the authors aim to raise awareness of the work done by the EUCERD Joint Action on behalf of the rare disease community and the policies established.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Keywords:  European Commission; European Reference Networks; Joint Actions; Rare disease policy; Registries

Mesh:

Year:  2017        PMID: 28087401     DOI: 10.1016/j.ejmg.2017.01.002

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  4 in total

1.  Our greatest untapped resource: our patients.

Authors:  Matt Bolz-Johnson; Tom Kenny; Yann Le Cam; Ines Hernando
Journal:  J Community Genet       Date:  2021-04-21

Review 2.  Cysteamine revisited: repair of arginine to cysteine mutations.

Authors:  L Gallego-Villar; Luciana Hannibal; J Häberle; B Thöny; T Ben-Omran; G K Nasrallah; Al-N Dewik; W D Kruger; H J Blom
Journal:  J Inherit Metab Dis       Date:  2017-06-22       Impact factor: 4.982

3.  Shaping national plans and strategies for rare diseases in Europe: past, present, and future.

Authors:  Victoria Hedley; Valentina Bottarelli; Ariane Weinman; Domenica Taruscio
Journal:  J Community Genet       Date:  2021-05-05

4.  Correction of a Factor VIII genomic inversion with designer-recombinases.

Authors:  Felix Lansing; Liliya Mukhametzyanova; Teresa Rojo-Romanos; Kentaro Iwasawa; Masaki Kimura; Maciej Paszkowski-Rogacz; Janet Karpinski; Tobias Grass; Jan Sonntag; Paul Martin Schneider; Ceren Günes; Jenna Hoersten; Lukas Theo Schmitt; Natalia Rodriguez-Muela; Ralf Knöfler; Takanori Takebe; Frank Buchholz
Journal:  Nat Commun       Date:  2022-01-20       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.